ホーム › 急性骨髄性白血病 › オクラホマ › Oklahoma City
Oklahoma City、OKにおける急性骨髄性白血病の臨床試験
Oklahoma Cityとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mercy Hospital Oklahoma City, Oklahoma City
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- University of Oklahoma Health Sciences Center, Oklahoma City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
被験者募集中第1相
- University of Oklahoma Health Sciences Center, Oklahoma City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- OU Health Stephenson Cancer Center, Oklahoma City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- University of Oklahoma Health Science Center, Oklahoma City
Pilot Imaging Study of Leukemia
被験者募集中第1相
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- OU Health Stephenson Cancer Center, Oklahoma City
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Oklahoma Cityにおける他の研究
- 非小細胞肺癌28件の研究
- 卵巣がん28件の研究
- 子宮内膜がん25件の研究
- 大腸癌22件の研究
- 前立腺がん21件の研究
- 肺がん19件の研究
- 乳がん17件の研究
- 転移性癌16件の研究
- がん（全種類）14件の研究
- 頭頸部扁平上皮癌13件の研究
- 膀胱癌11件の研究
- 膵臓がん11件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。